FDA approves Novartis’ Fabhalta in C3 glomerulopathy
Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 glomerulopathy. Fabhalta is the first drug approved specifically to treat C3 glomerulopathy, or C3G ...
Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 glomerulopathy.
Fabhalta is the first drug approved specifically to treat C3 glomerulopathy, or C3G ...
